Two key structural domains in TDP-43 that contribute to ALS pathogenesis were targeted for therapeutic screening: the RNA Recognition Motif 1 (RRM1) and N-terminal domain (NTD). This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.